Establishment Labs (NASDAQ:ESTA) Sets New 12-Month Low – Time to Sell?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $30.20 and last traded at $35.01, with a volume of 780735 shares trading hands. The stock had previously closed at $45.79.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. BTIG Research raised their target price on Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Citigroup raised their price objective on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a report on Tuesday, October 1st. Finally, Stephens raised shares of Establishment Labs to a “strong-buy” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Establishment Labs has an average rating of “Buy” and an average target price of $60.60.

Establishment Labs Stock Down 1.7 %

The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The business has a 50-day simple moving average of $43.75 and a two-hundred day simple moving average of $43.60. The stock has a market capitalization of $928.13 million, a P/E ratio of -12.85 and a beta of 1.15.

Institutional Investors Weigh In On Establishment Labs

Several large investors have recently made changes to their positions in ESTA. Assenagon Asset Management S.A. bought a new position in Establishment Labs during the 4th quarter valued at about $12,898,000. SkyView Investment Advisors LLC increased its holdings in shares of Establishment Labs by 30.5% during the third quarter. SkyView Investment Advisors LLC now owns 12,000 shares of the company’s stock worth $519,000 after buying an additional 2,805 shares in the last quarter. Barclays PLC raised its stake in shares of Establishment Labs by 9,643.3% in the third quarter. Barclays PLC now owns 31,471 shares of the company’s stock valued at $1,362,000 after acquiring an additional 31,148 shares during the last quarter. Redmile Group LLC raised its stake in shares of Establishment Labs by 22.9% in the third quarter. Redmile Group LLC now owns 261,803 shares of the company’s stock valued at $11,328,000 after acquiring an additional 48,779 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Establishment Labs by 210.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 49,400 shares of the company’s stock worth $2,138,000 after acquiring an additional 33,507 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.